Vuno Inc (338220) Fair Value & Analysis
Healthcare · KR · Market cap 130B KRW
Fair value as of: Jun 24, 2026
Analysis
Vuno Inc (338220) currently trades at 7,350 KRW, while our model-based Fair Value estimate is 4,643 KRW — implying the stock looks roughly 36.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Vuno Inc. engages in the artificial intelligence medical software development and services business. The company provides medical AI solutions for analyzing various medical data and assisting in disease diagnosis. It also offers BoneAge, an AI diagnostic software for bone age assessment; DeepBrain, a brain parcellation for the quantitative analysis of neurodegenerative diseases and other neurological disorders; chest X-ray, a diagnostic support system for abnormalities in chest x-ray; fundus AI, an AI-based screening solution for various abnormalities in the fundus of the eye; DeepCARS, an AI-based cardiac arrest risk management system; and LungCT AI, an AI-based pulmonary lung nodule detection and reporting system. In addition, the company provides medical products under HATIV brand, such as HATIV K30, a kiosk-type medical device that measures electrocardiograms; HATIV P30, a medical ECG device; HATIV BP30, an automatic blood pressure monitoring device; and HATIV TP50T, an ear infr…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Vuno Inc (338220) undervalued?
What is the fair value of 338220?
What is the quality score of 338220?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.